{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:38:22Z","timestamp":1793410702842,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3 project PE_00000019 \u201cHEAL ITALIA"],"award-info":[{"award-number":["PNRR M4C2I1.3 project PE_00000019 \u201cHEAL ITALIA"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022 2022L273C9"],"award-info":[{"award-number":["PRIN 2022 2022L273C9"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"crossref","award":["PNRR M4C2I1.3 Heal Italia project PE00000019 CUP B"],"award-info":[{"award-number":["PNRR M4C2I1.3 Heal Italia project PE00000019 CUP B"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["PON Research and Innovation 2014-2020-DM 1062\/2021"],"award-info":[{"award-number":["PON Research and Innovation 2014-2020-DM 1062\/2021"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375656"],"award-info":[{"award-number":["PNRR-MAD-2022-12375656"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12372399"],"award-info":[{"award-number":["RF-2021-12372399"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,2,16]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liver disease. However, the impact of GLP-1RAs on the long-term risk of major adverse liver-related outcomes (MALOs) remains uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We performed a meta-analysis of observational cohort studies to quantify the magnitude and direction of the association between GLP-1RA use and MALOs in people with type 2 diabetes (T2D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>We systematically searched eligible cohort studies comparing GLP-1RA new users versus users of other glucose-lowering medications. The primary outcome was the cumulative incidence rates of MALOs. Secondary outcomes included hepatic decompensation events, hepatocellular carcinoma (HCC) and liver-related mortality. Random-effects models were used to calculate incidence rate ratios (IRRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>11 retrospective cohort studies with aggregate data on 1 467 220 patients with T2D (647\u2009903 GLP-1RA new users, 819\u2009317 non-users) were included. GLP-1RA use was significantly associated with a lower risk of MALOs (IRR 0.71, 95% CI 0.57 to 0.88) and hepatic decompensation (IRR 0.70, 95% CI 0.52 to 0.94). Association with reduced risk of HCC was also observed (IRR 0.82, 95% CI 0.61 to 1.11). Compared with other antidiabetic medications, GLP-1RAs showed superior effectiveness versus SGLT2 inhibitors in preventing MALOs (IRR 0.93, 95% CI 0.87 to 0.99), versus DPP-4 inhibitors in preventing hepatic decompensation (IRR 0.74, 95% CI 0.66 to 0.83) and versus insulin therapy in preventing HCC (IRR 0.32, 95% CI 0.13 to 0.80).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GLP-1RA use is associated with a lower risk of liver-related complications and hepatic decompensation in people with T2D. These findings suggest a role of GLP-1RAs in preventing liver-related complications beyond their beneficial cardiometabolic effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2024-334591","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T13:20:41Z","timestamp":1740662441000},"page":"815-824","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies"],"prefix":"10.1136","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5662-2162","authenticated-orcid":false,"given":"Ciro","family":"Celsa","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"},{"name":"Department of Surgery & Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Tulone","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacinta","family":"Ciancimino","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Infantino","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Di Maria","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, UK"},{"name":"Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Enea","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6329","authenticated-orcid":false,"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2579","authenticated-orcid":false,"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Verona, Verona, Italy"},{"name":"Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (VR), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-1914","authenticated-orcid":false,"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-9673","authenticated-orcid":false,"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025090723373321000_74.5.815.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"2025090723373321000_74.5.815.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"2025090723373321000_74.5.815.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6"},{"key":"2025090723373321000_74.5.815.4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17981"},{"key":"2025090723373321000_74.5.815.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.05.003"},{"key":"2025090723373321000_74.5.815.6","doi-asserted-by":"crossref","unstructured":"Estes C , Anstee QM , Arias-Loste MT , et al . n.d. Modeling NAFLD disease burden in China. 69:896\u2013904. doi:10.1016\/j.jhep.2018.05.036","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"2025090723373321000_74.5.815.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y"},{"key":"2025090723373321000_74.5.815.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002"},{"key":"2025090723373321000_74.5.815.9","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040121","article-title":"Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?","volume":"11","author":"Tacelli","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025090723373321000_74.5.815.10","doi-asserted-by":"publisher","DOI":"10.1002\/cld.650"},{"key":"2025090723373321000_74.5.815.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334023"},{"key":"2025090723373321000_74.5.815.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"2025090723373321000_74.5.815.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2025090723373321000_74.5.815.14","unstructured":"Novo nordisk a\/s: semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and mash resolution in the essence trial. 2024."},{"key":"2025090723373321000_74.5.815.15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687"},{"key":"2025090723373321000_74.5.815.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.06.004"},{"key":"2025090723373321000_74.5.815.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962"},{"key":"2025090723373321000_74.5.815.18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025090723373321000_74.5.815.19","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2025090723373321000_74.5.815.20","doi-asserted-by":"crossref","unstructured":"Sterne JA , Hern\u00e1n MA , Reeves BC , et al . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355. doi:10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"2025090723373321000_74.5.815.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.010"},{"key":"2025090723373321000_74.5.815.22","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13751"},{"key":"2025090723373321000_74.5.815.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03228-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"BMC Med"},{"key":"2025090723373321000_74.5.815.24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17925"},{"key":"2025090723373321000_74.5.815.25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.04.029"},{"key":"2025090723373321000_74.5.815.26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025090723373321000_74.5.815.27","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000712"},{"key":"2025090723373321000_74.5.815.28","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00338-7"},{"key":"2025090723373321000_74.5.815.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108667"},{"key":"2025090723373321000_74.5.815.30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.5"},{"key":"2025090723373321000_74.5.815.31","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12903"},{"key":"2025090723373321000_74.5.815.32","doi-asserted-by":"crossref","unstructured":"Newsome PN , Sanyal AJ , Engebretsen KA , et al . Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis. 2024;60:1525\u201333. doi:10.1111\/apt.18331","DOI":"10.1111\/apt.18331"},{"key":"2025090723373321000_74.5.815.33","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"key":"2025090723373321000_74.5.815.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"2025090723373321000_74.5.815.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.033"},{"key":"2025090723373321000_74.5.815.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-334591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:37:40Z","timestamp":1757313460000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-334591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/gutjnl-2024-334591"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-334591","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}